Trans-activating crRNA (tracrRNA) 2

[{"image":"https://icons.cdn.biorender.com/w75xh75/5cbf84f837bbd33300faea30/5cbf84b837bbd33300faea22.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5cbf84f837bbd33300faea30/5cbf84b837bbd33300faea22.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5cbf84f837bbd33300faea2f/5cbf84b837bbd33300faea22.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5cbf84f837bbd33300faea2f/5cbf84b837bbd33300faea22.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5cbf84f837bbd33300faea2e/5cbf84b837bbd33300faea22.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5cbf84f837bbd33300faea2e/5cbf84b837bbd33300faea22.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5cbf84f837bbd33300faea2d/5cbf84b837bbd33300faea22.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5cbf84f837bbd33300faea2d/5cbf84b837bbd33300faea22.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5cbf84f837bbd33300faea2c/5cbf84b837bbd33300faea22.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5cbf84f837bbd33300faea2c/5cbf84b837bbd33300faea22.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5cbf84f837bbd33300faea2b/5cbf84b837bbd33300faea22.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5cbf84f837bbd33300faea2b/5cbf84b837bbd33300faea22.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5cbf84f837bbd33300faea2a/5cbf84b837bbd33300faea22.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5cbf84f837bbd33300faea2a/5cbf84b837bbd33300faea22.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5cbf84f837bbd33300faea29/5cbf84b837bbd33300faea22.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5cbf84f837bbd33300faea29/5cbf84b837bbd33300faea22.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5cbf84f837bbd33300faea28/5cbf84b837bbd33300faea22.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5cbf84f837bbd33300faea28/5cbf84b837bbd33300faea22.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5cbf84f837bbd33300faea27/5cbf84b837bbd33300faea22.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5cbf84f837bbd33300faea27/5cbf84b837bbd33300faea22.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5cbf84f837bbd33300faea26/5cbf84b837bbd33300faea22.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5cbf84f837bbd33300faea26/5cbf84b837bbd33300faea22.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5cbf84f837bbd33300faea25/5cbf84b837bbd33300faea22.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5cbf84f837bbd33300faea25/5cbf84b837bbd33300faea22.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5cbf84f837bbd33300faea24/5cbf84b837bbd33300faea22.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5cbf84f837bbd33300faea24/5cbf84b837bbd33300faea22.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5cbf84f837bbd33300faea23/5cbf84b837bbd33300faea22.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5cbf84f837bbd33300faea23/5cbf84b837bbd33300faea22.png"}]